

Steps taken after granting the Marketing Authorisation

For procedures finalised after 1 September 2004 please refer to module 8B

- The Marketing Authorisation Holder submitted to the EMEA on 29 December 1998 an application for one type I variation falling within the scope of item No 8 of Annex I to Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:
A change in the qualitative composition of immediate packaging material.
On 05 February 1999, the EMEA approved the variation. This variation required amendments to annexes I and IIIB of the Commission Decision. Revised EMEA notification dated 01 April 1999 regarding EU numbers. The European Commission amended the Decision on 11 June 1999.
- The Marketing Authorisation Holder submitted to the EMEA on 04 February 1999 an application for one type I variation falling within the scope of item No 1 of Annex I to Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:
An alternative manufacturing site for the finished product.
On 22 March 1999, the EMEA approved the variation. This variation required amendments to annexes II and IIIB of the Commission Decision.. The European Commission amended the Decision on 16 July 1999.
- The Marketing Authorisation Holder submitted to the EMEA on 04 February 1999 an application for one type I variation falling within the scope of item No 16 of Annex I to Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:
A change in the batch size of the finished product.
On 22 March 1999, the EMEA approved the variation. This variation did not require any amendment to the Commission Decision.
- The Marketing Authorisation Holder submitted to the EMEA on 08 April 1999 an application for one type I variation falling within the scope of item No 32 of Annex I to Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:
A new engraving on the tablets.
On 13 May 1999, the EMEA approved the variation. This variation required amendments to annexes I and IIIB of the Commission Decision. The European Commission amended the Decision on 08 July 1999.
- The Marketing Authorisation Holder submitted to the EMEA on 08 April 1999 an application for one type I variation falling within the scope of item No 14 of Annex I to Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:
A change in the specification of the active substance.
On 06 July 1999, the EMEA approved the variation. This variation did not require any amendment to the Commission Decision.
- On 26 April 1999, the Marketing Authorisation Holder submitted a Type II variation application in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of the variation related to the update of the Summaries of Product Characteristics and Package Leaflets according to the assessment of the second PSUR
On 20 May 1999 the CPMP approved the variation. The variation required amendments in annexes I and IIIB of the Commission Decision. The European Commission amended the Decision on 07 September 1999.

- Between 31 August 1999 and 4 May 2000, the EMEA issued Notifications for the approval of five type I variations concerning
 - change in the manufacturer of the active substance,
 - change in the batch size of the active substance,
 - minor change of manufacturing process of the active substance,
 - change in the manufacturer of the active substance,
 - change of the manufacturing site for part of the manufacturing process of the medicinal product.

These variations did not require any amendment to the Commission decision.

- On 07 February 2000, the Marketing Authorisation Holder submitted a Type II variation application in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of the variation related to the update of the Summaries of Product Characteristics according to the assessment of the fourth PSUR. On 12 April 2000 the CPMP approved the variation. At the same time, annex II of the Commission Decision has been updated. The variation required amendments in annexes I and II of the Commission Decision. The European Commission amended the Decision on 13 July 2000.
- On 15 May 2000, the Marketing Authorisation Holder submitted a Type II variation application in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The Marketing Authorisation Holder applied for a new formulation of the film-coated tablet containing a new polymorphic form of the active substance. In addition to the subsequent changes in the SPC, Labelling and PL, these annexes have been revised according to the latest templates. On 21 September 2000 the CPMP approved the variation. The variation required amendments in annexes I, IIIA and IIIB of the Commission Decision. The European Commission amended the Decision on 15 January 2001.
- On 26 July 2000, the Marketing Authorisation Holder requested to introduce changes to an aspect of the labelling not connected to the Summary of Product Characteristics, by means of a Notification under Article 10(3) of Directive 92/27/EEC. Following EMEA's Notification on 1 August 2000, the European Commission amended the Decision (Annex IIIA) on 25 September 2000.
- On 5 September 2000, the Marketing Authorisation Holder submitted a Type II variation application in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The Marketing Authorisation Holder applied for an update of the SPC following the assessment of a PSUR. On 16 November 2000 the CPMP approved the variation. The variation required amendments in annexes I and IIIB of the Commission Decision. The European Commission amended the Decision on 6 March 2001.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

Scope	Application number	Type of modification ¹	Notification/Opinion issued on ²	Commission Decision Issued/amended on
Update of Summary of Product Characteristics (sections 4.4, 4.5 and 4.8) and Package Leaflet following the assessment of the 5 th PSUR.	II/0016	II	29.03.01	16.07.01
Batch size of active substance	I/0017	I	04.03.01	N/A
Minor change of manufacturing process of the active substance	I/0018	I	04.03.04	N/A
Change in the name of a manufacturer of the active substance	I/0019	I	19.07.01	N/A
Update of the Summary of Product Characteristics and Package Leaflet	II/0020	II	23.08.01	29.01.02
Change in the name and/or address of the marketing authorisation holder	I/0021	I	03.10.01	19.02.02
Additional indication (Acute Coronary Syndrome)	II/0022	II	28.05.02	09.09.02
Change following modification(s) of the manufacturing authorisation(s)	I/0023	I	13.12.01	19.02.02
Change in or addition of manufacturing site(s) for part or all of the manufacturing process	I/0025	I	16.05.02	19.06.02
Change in the name of a manufacturer of the medicinal product	I/0026	I	27.05.02	27.05.02
Extension of shelf-life as foreseen at time of authorisation	I/0027	I	20.12.02	03.02.03
Change in test procedure for starting material/intermediate used in manuf. of active substance	I/0028	I	19.02.03	03.03.03
Batch size of active substance	I/0029	I	10.01.03	16.01.03
Change in the batch size of finished product	I/0030	I	27.03.03	01.04.03
Minor changes in manufacture of the medicinal product	I/0031	I	27.03.03	01.04.03
Change in pack size for a medicinal product	I/0032	I	14.02.03	20.03.03
Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	N/0034	N	04.04.03	12.05.03
Renewal	R/0035	R	22.05.03	08.10.03
Change(s) to the manufacturing process for the active substance	II/0036	II	25.09.03	02.10.03
Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	N/0037	N	20.11.03	22.12.03
Update of Summary of Product Characteristics and Package Leaflet	II/0038	II	03.06.04	02.08.04
Replacement/add. of manufacturing site: Secondary packaging site and change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing	IA/0039	IA	11.06.04	-

¹ In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: **I** refers to a minor variation (Type I variation); **II** refers to a major variation (Type II variation); **I/II** refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; **X** refers to an Annex II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

² For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.